Business
EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX
EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nEDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nEDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that EDISON Group issued a Healthcare QuickView publication on the company prepared by Analyst Will Manuel.\nThe publication details Company's plans for Phase I/II(a) clinical studies for its colorectal cancer treatment drug candidate RCC-33, as well as other recent updates on company's activities.\nTo read the EDISON Group QuickView please click here.\nRead more:\nRecent expansion of Company's IP Portfolio with filing of 2 new Provisional Patents; Recent expansion of Cannabics Pharmaceuticals' Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.); Recent expansion of Cannabics Pharmaceuticals' Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.\nAbout Cannabics Pharmaceuticals:\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates ...